Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers

NCT04511039 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT04511039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1
Overall status
Recruiting
Start date
June 8, 2021
Completion date
April 1, 2029
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, clinical stage iii gastroesophageal junction adenocarcinoma, clinical stage iv gastroesophageal junction adenocarcinoma, clinical stage iva gastroesophageal junction adenocarcinoma, clinical stage ivb gastroesophageal junction adenocarcinoma a, locally advanced colorectal carcinoma, locally advanced gastroesophageal junction adenocarcinoma, metastatic colorectal adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, pathologic stage iii gastroesophageal junction adenocarcinoma, pathologic stage iiia gastroesophageal junction adenocarcinoma, pathologic stage iiib gastroesophageal junction adenocarcinoma, pathologic stage iv gastroesophageal junction adenocarcinoma, pathologic stage iva gastroesophageal junction adenocarcinoma, pathologic stage ivb gastroesophageal junction adenocarcinoma, postneoadjuvant therapy stage iii gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb gastroesophageal junction adenocarcinoma ajcc v8, stage iii colorectal cancer ajcc v8, stage iiia colorectal cancer ajcc v8, stage iiib colorectal cancer ajcc v8, stage iiic colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8